ClinicalTrials.gg
RecruitingNCT07378683Updated Jan 30, 2026

A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery

An interventional study of ML-Based Enhanced Intervention Package for SSI Prevention and Standard Postoperative Care in Surgical Site Infection (SSI) and Central Nervous System Tumor, sponsored by Ming Yang. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Ming Yang · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2025, registered Jan 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Surgical Wound Infection with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Surgical Wound Infection · China.

Planned enrollment
4th of 10
500 · median 359
Started
2025
the only one that year
No phase
9 of 14
4 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Ming Yang

Among the 14 studies in Surgical Wound Infection with a site in China, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 12th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

4 of the 14 studies in Surgical Wound Infection with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Surgical Wound Infection with a site in China, or all of them as a file.
02

Study summary

  1. Study Background For patients undergoing brain or spinal tumor surgery, postoperative surgical wound infection (known as "surgical site infection," SSI) is a recognized risk. Once an infection occurs, it may complicate and prolong the recovery process. Currently, doctors primarily rely on clinical experience to judge which patients are at higher risk of infection. Our research team has previously developed an intelligent prediction model (a machine learning tool) that can very accurately identify which patients are at higher risk of postoperative infection. This study aims to validate whether implementing enhanced preventive measures for high-risk patients in advance, based on the model's predictions, can effectively reduce the occurrence of infection.
  2. Study Purpose The primary purpose of this study is to validate whether an individualized intervention strategy based on an intelligent prediction model can effectively reduce the incidence of surgical site infection in patients after central nervous system tumor surgery. Simultaneously, we will also evaluate the safety of this strategy, its impact on patient hospital stay length and medical costs, as well as its feasibility in practical clinical application.
  3. Study Design Type: This is a prospective, single-center clinical validation study. "Prospective" means the research plan is established first, followed by patient recruitment and data collection according to the plan; "single-center" indicates the study is conducted solely at the Chinese Academy of Medical Sciences Cancer Hospital.

    Process: For all patients who consent to participate in this study, within 72 hours after surgery, the research system will automatically calculate their infection risk based on 8 key clinical indicators (such as blood test results, medical history, etc.).

    High-Risk Group (model-predicted infection probability ≥50%): Will receive a set of enhanced, individualized infection prevention measures (e.g., adjusted antibiotic regimen, enhanced nutritional support, closer monitoring).

    Low-Risk Group (model-predicted infection probability \<50%): Will receive the current standard, high-quality postoperative care.

    Duration: The study is planned to run from February 2026 to October 2029. Each participating patient will be followed for 3 months (90 days) to observe whether infection occurs.

    Sample Size: It is planned to recruit approximately 500 eligible patients.

  4. Primary Evaluation Indicators Primary Indicator: The incidence of surgical site infection within 90 days after surgery. The diagnosis of infection will be made by experts who are unaware of the patient's group assignment, strictly following international standards.

    Secondary Indicators: Include the accuracy of the intelligent prediction model in practical use, patient hospital stay length, other infection-related complications, medical costs, and the adoption rate of the model's recommendations by physicians.

  5. Eligibility Criteria (Inclusion Criteria Summary)

    You may be eligible to participate in this study if you meet the following conditions:

    Diagnosed with a brain or spinal tumor and scheduled for elective surgery. Aged 18 years or older. Expected survival exceeds 3 months and able to cooperate with postoperative follow-up.

    Voluntary participation and signing of a written informed consent form. (Note: This study has detailed exclusion criteria. Final confirmation of whether all criteria are met will be determined by your study doctor.)

  6. Patients' Rights and Safety Voluntary Participation: Participation in this study is entirely voluntary. You have the right to withdraw from the study at any time, which will not affect the quality of any normal medical services you are entitled to at our hospital or your relationship with it.

    Informed Consent: Before the study begins, your study doctor will explain all study procedures, potential risks, and benefits in detail, and you will sign an "Informed Consent Form." Privacy Protection: All your personally identifiable information will be kept strictly confidential. Codes will replace your name and other identifiable information in research analyses and reports.

    Safety Assurance: This study has been reviewed and approved by the hospital's Ethics Committee. We have established an independent Data Safety Monitoring Board to monitor the study's safety throughout. Clinical trial liability insurance has been purchased for all participants to cover damages related to the trial.

  7. Contact Information

If you would like to learn more about this study, please contact us via:

Principal Investigator: Dr. Yang Ming National Cancer Center/National Clinical Research Center for Cancer/Cancer Research Unit: Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

03

Conditions studied

  • Surgical Site Infection (SSI)
  • Central Nervous System Tumor

Keywords

  • surgical site infection
  • central nervous system tumor
  • machine learning
  • explainable artificial intelligence
  • SHAP
  • clinical decision support system
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a confirmed primary or central nervous system (brain or spinal) tumor.
  2. Scheduled for elective craniotomy or spinal tumor resection surgery.
  3. Age ≥ 18 years.
  4. Expected survival > 3 months, and able/willing to comply with postoperative follow-up.
  5. Voluntary participation and provision of written .

Exclusion criteria

Exclusion Criteria:

  1. Presence of active systemic or local surgical site infection before surgery.
  2. Use of therapeutic antibiotics for any reason within 72 hours prior to surgery.
  3. Concurrent severe conditions, or chronic use of high-dose immunosuppressants.
  4. Pregnancy or lactation.
  5. Known or severe allergy to the antibiotics planned for use in the study.
  6. Any other condition that, in the investigator's judgment, may affect study participation or outcome assessment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    High-Risk: ML-Based Intervention

    This is the High-Risk Intervention Group. Patients identified as high-risk for SSI (predicted probability ≥ 50%) by the LightGBM model within 72 hours post-surgery receive an enhanced, individualized intervention package, which may include an escalated antibiotic regimen, intensified nutritional support, and closer monitoring.

    Other: ML-Based Enhanced Intervention Package for SSI Prevention

  • Active comparator
    Low-Risk: Standard Care

    This is the Low-Risk Routine Care Group. Patients identified as low-risk for SSI (predicted probability \< 50%) by the same model receive the current standard postoperative care of the hospital, following established clinical pathways without the enhanced intervention package. This arm serves as the control.

    Other: Standard Postoperative Care

Interventions

  • OtherML-Based Enhanced Intervention Package for SSI Prevention

    This is a comprehensive, individualized intervention package administered to patients identified as high-risk for surgical site infection (SSI) by a machine learning (LightGBM) model. The package is activated postoperatively and may include, but is not limited to: 1) \*\*Escalated/optimized antibiotic prophylaxis regimen\*\*; 2) \*\*Intensified nutritional support protocols\*\*; 3) \*\*Enhanced monitoring\*\* of vital signs and wound status. The specific components are tailored based on the patient's risk profile and clinical context. The intervention aims to validate the effectiveness of a model-driven strategy in reducing SSI incidence.

  • OtherStandard Postoperative Care

    This intervention represents the current standard of care provided to patients after elective central nervous system tumor surgery at this institution. It includes routine antibiotic prophylaxis, standard wound care, basic vital signs monitoring, and follow-up according to established clinical pathways. Patients in this group do not receive the enhanced, study-specific intervention package and serve as the control population for comparison.

06

What researchers measure

Primary outcomes

  1. Incidence of surgical site infection within 90 days postoperatively

    The occurrence of a surgical site infection (SSI) following central nervous system tumor surgery, diagnosed according to the U.S. National Healthcare Safety Network (NHSN) criteria. Diagnosis will be adjudicated by a blinded independent endpoint adjudication committee.

    Time frame: 90 days post-surgery

07

Study locations

1 of 1 sites recruiting
  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, PUMC 10010, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in this article (including demographics, clinical characteristics, model input variables, and primary endpoint) will be shared. The study protocol, statistical analysis plan, and informed consent form will also be made available. Data will become available following publication of the primary results in a peer-reviewed journal and will be accessible for at least 5 years. Access will be granted to researchers whose methodologically sound proposals have been approved by a scientific review committee, via a controlled-access data repository or upon request.

Supporting information: Analytic code

Time frame: The de-identified IPD and supporting documents will become available no later than 6 months after the publication of the primary study findings in a peer-reviewed journal. The data will be accessible for a minimum of 5 years thereafter.

Access criteria: Access to IPD will be granted to qualified researchers for legitimate scientific research purposes. Requestors must submit a methodologically sound research proposal to the study Principal Investigator (PI) for review by a designated scientific committee. Proposals will be evaluated for scientific merit, feasibility, and ethical compliance. Data requestors will be required to sign a data use agreement (DUA) prohibiting re-identification attempts, unauthorized redistribution, and commercial use.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2029, 52 months after the start.

Of 202 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 52 months is above that.

Counting every sponsor, half of 209 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 30, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Oct 30, 2029
CompletionEst.
Oct 30, 2029
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07378683
Lead sponsor
Ming Yang
Responsible party
Ming Yang (Clinical Professor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Sponsor-investigator
First posted
Jan 30, 2026
Start date
Jun 1, 2025
Primary completion
Oct 30, 2029 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Jan 30, 2026

Study contacts

Ming Yang, MD
Contact
yangming@cicams.ac.cn
+8613810655237

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion